Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
Submitted by
admin
on July 11, 2018 - 10:15am
Source:
CP Wire
News Tags:
Takeda
Ninlaro
Multiple Myeloma
Headline:
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
snippet:
Ninlaro maintenance therapy resulted in a statistically significant improvement in progression-free survival (PFS) versus placebo.
Ninlaro has orphan drug status in both the US and Europe for multiple myeloma and AL amyloidosis
Six additional pivotal trials under way (multiple myeloma and amyloidosis)
Takeda CEO expects Ninlaro will surpass blockbuster Velcade as the company’s biggest-ever cancer product.
Do Not Allow Advertisers to Use My Personal information
